4889.T
Renascience Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 999.00
−0.70%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 68.0M | 68.0M | 132.0M | 194.0M | 100.0M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 64.2M | 64.2M | 128.9M | 165.6M | 100.3M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | — | — | — | — | — |
| Cost and Expenses | 424.0M | 424.0M | 310.0M | 446.0M | 433.0M |
| Operating Income (EBIT) | (356.0M) | (356.0M) | (178.0M) | (252.0M) | (333.0M) |
| Non-Operating | |||||
| Interest Income | 3.5M | 3.5M | 924.0K | 24.0K | 26.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 56.6M | 56.6M | (160.0K) | — | — |
| Non-Operating Income (excl Interest) | 27.0M | 64.0M | 168.0K | 436.0K | 5.0K |
| EBT (Pre-Tax Income) | (300.3M) | (300.3M) | 143.8M | (256.4M) | (333.8M) |
| Income Tax Expense | 1.0M | 1.0M | 30.3M | 2.0M | 2.0M |
| Bottom Line | |||||
| Net Income | (301.0M) | (301.0M) | 113.0M | (258.0M) | (335.0M) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (301.0M) | (301.0M) | 113.0M | (258.0M) | (335.0M) |
| Per Share | |||||
| Basic EPS | (¥24) | (¥23) | ¥9 | (¥20) | (¥26) |
| Diluted EPS | (¥24) | (¥23) | — | — | — |
| Revenue Per Share | ¥5 | ¥5 | ¥10 | ¥15 | ¥8 |
| Shares | |||||
| Basic Shares Outstanding | 12.9M | 12.9M | 12.7M | 12.7M | 12.7M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | — | (177.9M) | (250.2M) | (331.6M) |
| D&A | — | — | 62.0K | 1.8M | 1.4M |
| EBIT | (356.0M) | (356.0M) | (178.0M) | (252.0M) | (333.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026